Thrivent Financial for Lutherans Has $86.65 Million Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Thrivent Financial for Lutherans lowered its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 3.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,058,733 shares of the company's stock after selling 127,866 shares during the period. Thrivent Financial for Lutherans owned 0.21% of Kenvue worth $86,654,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of KVUE. Grove Bank & Trust grew its holdings in Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after acquiring an additional 947 shares during the period. Geneos Wealth Management Inc. acquired a new stake in Kenvue during the 4th quarter worth $29,000. SRS Capital Advisors Inc. grew its holdings in Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after acquiring an additional 571 shares during the period. Fortitude Family Office LLC grew its holdings in Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock worth $32,000 after acquiring an additional 777 shares during the period. Finally, Versant Capital Management Inc grew its holdings in Kenvue by 300.8% during the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock worth $41,000 after acquiring an additional 1,441 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Stock Down 0.2 %

KVUE traded down $0.05 during trading on Friday, hitting $23.34. The company had a trading volume of 35,334,673 shares, compared to its average volume of 16,169,860. The company has a market capitalization of $44.61 billion, a PE ratio of 44.04, a PEG ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The firm's 50-day moving average price is $22.08 and its 200 day moving average price is $22.43. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Remove Ads

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, equities analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were given a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.51%. Kenvue's dividend payout ratio (DPR) is presently 154.72%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Piper Sandler lifted their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research report on Monday, February 24th. Barclays reduced their price target on shares of Kenvue from $23.00 to $21.00 and set an "equal weight" rating on the stock in a research report on Friday, January 17th. UBS Group reduced their price target on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research report on Friday, February 7th. Royal Bank of Canada reissued a "sector perform" rating and set a $24.00 price target on shares of Kenvue in a research report on Monday, February 3rd. Finally, Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a "buy" rating to a "hold" rating and reduced their price target for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $23.75.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.